M. Kakegawa

Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab

K. Naoki, H. Ishiyama, M. Katagiri, 2020, Thoracic cancer.

First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study

K. Naoki, Takashi Sato, S. Igawa, 2021, Investigational New Drugs.

Significance of Immune Checkpoint Inhibitors in Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy Prior to the Approval of Durvalumab

K. Naoki, H. Ishiyama, M. Katagiri, 2019 .

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer

K. Naoki, Takashi Sato, S. Igawa, 2021, Cancer management and research.

First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study

K. Naoki, Takashi Sato, S. Igawa, 2021, Investigational New Drugs.

Implementation of clinical sequencing for molecular profiling in patients with advanced cancer.

K. Nishio, K. Naoki, K. Nakagawa, 2021, Cancer biomarkers : section A of Disease markers.